Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD)

Introduction

Hong Kong Pharma Digital Technology Holdings Limited (“HKPD”) is a Hong Kong–based provider of over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain services. Trading on the Nasdaq Capital Market under the ticker HKPD, the company provides services including wholesale, import/export, customs clearance, warehousing, packaging, and final-mile delivery for merchants selling OTC medicines from Hong Kong to Mainland China.

Corporate Structure

• Incorporation: Established in 2019 and headquartered in Hong Kong.
• Subsidiaries:
  • Joint Cross Border Logistics Company Limited (supply chain services)
  • V-Alliance Technology Supplies Limited (procurement and distribution)
• Operational Capacity:
  • Over 1,000,000 SKUs in inventory
  • More than 5,270,000 parcels transferred to date
• Regulatory Compliance: Licensed in Hong Kong, enlists products with the Hong Kong Department of Health, and secures import/export permits.

Developments and News

• January 15, 2025: The initial public offering closed, issuing 1,403,685 ordinary shares at US $4.00 per share, raising gross proceeds of US $5.61 million.
• January 17, 2025: Shares began trading on Nasdaq under “HKPD” following consolidation into a single class of ordinary shares.
• March 28, 2025: The company published unaudited results for the six months ended September 30, 2024:
  • Net revenues of US $11.09 million (58.9% increase compared to H1 2023)
  • Gross profit of US $1.91 million (42.6% increase)
  • Net income of US $0.83 million (232.6% increase)
• Press Releases: Issued updates on January 23, 2025; media contact via .

Financial and Strategic Analysis

Key Trading Metrics (As of June 2, 2025)

Metric	Value
Share Price	US $1.70
Day’s Change	+45.30%
Volume	4,095,070
52-Week Range	US $0.81 – US $3.79
Market Capitalization	US $18.6 million

Selected Financial Ratios (TTM)

Ratio	Value
P/E	9.97
EPS	0.17
Price/Sales	0.62
Price/Book	2.40
EV/Revenue	0.72
EV/EBITDA	4.57
Profit Margin	9.19%
Net Income (TTM)	US $1.91 M
Revenue (TTM)	US $20.77 M

Balance Sheet Highlights

• Total Cash (mrq): US $0.36 million
• Debt/Equity (mrq): 43.88%

Strategic Initiatives

• Technology Upgrade: Investing in supply chain enterprise resource planning (ERP) systems.
• Capacity Expansion: Procuring warehouse equipment to improve operational efficiency.
• Sales & Marketing: Expanding the sales team to capture additional market share.
• Operational Efficiency: Improving logistics to enhance profitability.

Market Position and Industry Context

• Sector: OTC pharmaceutical cross-border e-commerce, catering to Mainland Chinese consumers seeking non-prescription medicines from overseas.
• Competitive Landscape: Competes with integrated logistics and e-commerce service providers, differentiating through comprehensive service offerings and expertise in regulatory compliance.
• Market Drivers:
  • Increasing demand for imported healthcare products in Mainland China
  • Stringent regulatory requirements affecting market entry
  • Growth of cross-border e-commerce platforms (e.g., Tmall Global, JD Worldwide)
• Valuation Context: Trading at a Price/Sales ratio below 1.0, indicating conservative market expectations compared to peers in logistics and pharmaceutical distribution.

tl;dr

On January 15, 2025, HKPD closed its IPO, raising US $5.61 million at US $4.00 per share. As of June 2, 2025, shares trade at US $1.70 (increased 45.30% intraday) with a market cap of US $18.6 million. H1 2024 revenues rose 58.9% to US $11.09 million and net income increased 232.6%. The company plans to allocate IPO proceeds towards ERP upgrades, warehouse equipment, and sales expansion to support growth in cross-border e-commerce.